|

ESG401 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 3: 2

Top Sponsors

  • Qilu Pharmaceutical Co., Ltd.2

Indications

  • Breast Cancer2
  • Cancer2
  • Metastatic Breast Cancer1
  • Triple Negative Breast Cancer (TNBC)1

Other2 trials

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.